Stocks › BCRX
BIOCRYST PHARMACEUTICALS INC
BCRX·Nasdaq·
United States·USD
United States·USD$7.95
-0.15 (-1.85%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
BCRX
BIOCRYST PHARMACEUTICALS INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BCRXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of BCRX by members of U.S. Congress · 5 on record · 2 in the last 12 months
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Gilbert Ray Cisneros, Jr.House · D · CA |
BCRXBIOCRYST PHARMACEUTICALS INC · Stock |
Purchase $1,001 - $15,000 |
Sep 4, 2026 | Jul 10, 2026 | Filing ↗ |
| Gilbert Ray Cisneros, Jr.House · D · CA |
BCRXBIOCRYST PHARMACEUTICALS INC · Stock |
Purchase $1,001 - $15,000 |
Dec 15, 2025 | Nov 13, 2025 | Filing ↗ |
 Josh GottheimerHouse · D · NJ |
BCRXBIOCRYST PHARMACEUTICALS INC · Stock |
Purchase $1,001 - $15,000 |
Nov 11, 2023 | Oct 16, 2023 | Filing ↗ |
| Josh GottheimerHouse · D · NJ |
BCRXBIOCRYST PHARMACEUTICALS INC · Stock |
Sale $1,001 - $15,000 |
Oct 15, 2023 | Sep 15, 2023 | Filing ↗ |
| Josh GottheimerHouse · D · NJ |
BCRXBIOCRYST PHARMACEUTICALS INC · Stock |
Purchase $1,001 - $15,000 |
Sep 16, 2022 | Aug 11, 2022 | Filing ↗ |
Whale Activity
Position changes in BCRX reported for 2026-09-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| DOLIVER ADVISORS, LP | 304.3K | $2.5M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by BCRX insiders, by quarter · Form 4
Recent Insider Transactions
1,039 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Milne Jill C.Director | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| Galson Steven KDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| LEVIN ALAN GDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| Frank StevenDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| SANDERS MACHELLEDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| MILANO VINCENTDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| Stonehouse Jon PDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| McKee Amy EDirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| HEGGIE THERESADirector | Grant / award | +15.3K | $0.00 | $0 | Jun 11, 2026 | Form 4 ↗ |
| Milne Jill C.Director | Grant / award | +1,262 | $8.91 | $11K | May 29, 2026 | Form 4 ↗ |
| Stonehouse Jon PDirector | Grant / award | +631 | $8.91 | $6K | May 29, 2026 | Form 4 ↗ |
| McKee Amy EDirector | Grant / award | +631 | $8.91 | $6K | May 29, 2026 | Form 4 ↗ |
| MILANO VINCENTDirector | Grant / award | +1,122 | $8.91 | $10K | May 29, 2026 | Form 4 ↗ |
| Frank StevenDirector | Grant / award | +1,262 | $8.91 | $11K | May 29, 2026 | Form 4 ↗ |
| McKee Amy EDirector | Sale | −11.2K | $8.97 | $100K | May 18, 2026 | Form 4 ↗ |
| Barnes Alane PChief Legal Officer | Sale | −62.5K | $9.54 | $596K | May 13, 2026 | Form 4 ↗ |
| Barnes Alane PChief Legal Officer | Option exercise | +62.5K | $5.04 | $315K | May 13, 2026 | Form 4 ↗ |
| Menon SandeepChief R&D Officer | Grant / award | +205.2K | $0.00 | $0 | Apr 6, 2026 | Form 4 ↗ |
| HEGGIE THERESADirector | Sale | −49.9K | $10.11 | $505K | Mar 20, 2026 | Form 4 ↗ |
| HEGGIE THERESADirector | Option exercise | +49.9K | $6.30 | $315K | Mar 20, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding BCRX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 9.6M | $95.8M | 0.89% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 8.1M | $80.7M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 6.0M | $60.5M | 0.07% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.9M | $29.1M | 0.02% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.8M | $28.4M | 0.03% | Jun 30, 2026 |
| abrdn Healthcare Investors | 2.3M | $23.2M | 1.71% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 2.5M | $22.8M | 0.07% | Jul 31, 2026 |
| VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS | 2.3M | $22.6M | 0.19% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 2.1M | $21.5M | 0.14% | Jun 30, 2026 |
| abrdn Healthcare Opportunities Fund | 2.1M | $20.9M | 2.53% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list BCRX's shares (CUSIP 09058V103), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- RA Capital Healthcare Fund, L.P.SCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
Aug 14, 2026 · ↗ - Rajeev ShahSCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
Aug 14, 2026 · ↗ - Peter KolchinskySCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
Aug 14, 2026 · ↗ - RA Capital Management, L.P.SCHEDULE 13G/A · passive (13G) · 15.8M shares6.2%
Aug 14, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 15.2M shares6.0%
Aug 7, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 12.2M shares4.9%
May 12, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming biocryst pharmaceuticals as client
No lobbying filings found naming BIOCRYST PHARMACEUTICALS INC as the client.
- BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2018 Q3$10K
Filing ↗ - BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2018 Q2$20K
Filing ↗ - BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2018 Q1 · MED, DIS$20K
Filing ↗ - BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2017 Q4 · DIS, MED$20K
Filing ↗ - BAY BRIDGE STRATEGIES, INC.BIOCRYST PHARMACEUTICALS, INC. · 2017 Q3 · MED, DIS$20K
Filing ↗
Government Contracts
Federal awards to biocryst pharmaceuticals · USAspending
$182KAwarded · 2 contracts on record
U.S. Patents
Recent USPTO applications naming BIOCRYST PHARMACEUTICALS INC
No USPTO patent applications found for BIOCRYST PHARMACEUTICALS INC.
Annual Financials
From BCRX's 10-K filings · XBRL
No annual XBRL figures on record for BCRX. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in BCRX's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureAug 5, 2026
EDGAR ↗ - 8-K/A · Items 2.05Exit or disposal costsAug 4, 2026
EDGAR ↗ - 8-K · Items 2.05, 7.01, 9.01Exit or disposal costs · Reg FD disclosureJun 29, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 12, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureMay 6, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureMay 4, 2026
EDGAR ↗
About BIOCRYST PHARMACEUTICALS INC
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersDURHAM, NC
IncorporatedDE
SEC CIK0000882796 ↗